ICML 2025 | Efficacy of the ViPOR regimen in MCL: MRD responses

This meeting tomorrow I’m going to be presenting as an oral presentation the results of our VIPER cohort in mantle cell lymphoma. This builds upon our previous work using this regimen in diffuse large B-cell lymphoma and we wanted to expand that into mantle cell lymphoma given the high single-agent efficacy of these agents, these targeted agents in mantle cell. So overall, the regimen was extremely safe. Really, the hematologic toxicity was most common, but given the cyclic nature of the regimen, we really saw high-grade toxicities in under about 15% of cycles. And what was very remarkable to us and a little quite unexpected or quite expected was that the responses were very good. So all but one patient achieved a complete response to the VIPER regimen. And in the previous, the patients who were previously untreated, never received chemotherapy, it was all 100 percent of them achieved a complete remission. And this regimen is different from other targeted therapies, which are often given indefinitely or one, two years duration. It’s given for a very short duration, only six cycles, so 18 weeks or a little over four months and stop. And despite that overall short duration, over 90 percent, so 93 percent of patients previously treated with chemotherapy, and 95 percent of patients without chemotherapy were still in durable clinical remission at the two-year point. So we have some patients out past four years, so now we’re trying to assess that longevity. In terms of the MRD, we really saw a rapid and profound decrease in the MRD detectable rate after venetoclax was initiated with the second cycle of therapy. So it went from about 17% undetectable after the first cycle to upwards of about three-quarters, 75% undetectable after the second cycle and this was as high as 97% at the end of therapy. So these are very deep and durable remissions and now we continue to follow them to hopefully see how durable they are or if anyone is potentially cured with these novel therapies.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.